Latest News
Lupin spins out two oncology programmes to Kaveri Therapeutics
21 July 2026 - India-based global pharmaceutical company Lupin Limited (BSE: 500257) (NSE: LUPIN) announced on Tuesday the strategic spin-out of two oncology programmes, LNP7457 (PRMT5) and LNP8701 (SOS1), through its wholly owned subsidiary, Lupin I...
Fuse Oncology launches new prescribing and treatment-intent solution FuseRx
21 July 2026 - Fuse Oncology, a structured AI platform for radiation oncology, announced on Monday the launch of FuseRx, a prescribing and treatment-intent solution for radiation oncology.According to Fuse Oncology, FuseRx is the keystone of the Fuse...
AbelZeta's C-CAR168 receives EMA PRIME designation for Lupus Nephritis and Systemic Lupus Erythematosus
21 July 2026 - Clinical-stage biopharmaceutical company AbelZeta Pharma Inc announced on Monday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted PRIority MEdicines (PRIME) designation f...
Akagera Medicines reports positive first-in-human data for AKG-100
21 July 2026 - Clinical-stage biopharmaceutical company Akagera Medicines Inc, together with the TASK Clinical Research Center in South Africa, on Monday announced positive results from the single-ascending-dose (SAD) portion of the first-in-human Ph...
Argo Biopharma doses first participant in Phase I trial of factor XI targeting siRNA therapy
21 July 2026 - Argo Biopharmaceutical Co Ltd, a clinical-stage small interfering RNA (siRNA) therapeutics company, announced on Monday that the first participant has been dosed in its Phase I study of BW-41012, an investigational siRNA therapy target...